Clinical efficacy and safety of decitabine combined with CAG regimen in treatment of elderly patients with acute myeloid leukemia: a Meta-analysis
10.3760/cma.j.cn115356-20190702-00128
- VernacularTitle:地西他滨联合CAG方案治疗老年人急性髓系白血病临床效果及安全性的Meta分析
- Author:
Rong CHEN
1
;
Feng ZHANG
;
Guilan LAI
;
Yachun CHEN
;
Guoxian CUI
;
Jianzhen SHEN
Author Information
1. 福建省血液病研究所 福建省血液病学重点实验室 福建医科大学附属协和医院血液内科，福州 350001
- From:
Journal of Leukemia & Lymphoma
2020;29(8):488-494
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical efficacy and safety of decitabine combined with CAG regimen in treatment of elderly patients with acute myeloid leukemia (AML).Methods:Decitabine combined with CAG regimen (experimental group) and CAG regimen alone (control group) were used to treat elderly patients with AML. The randomized controlled trials (RCT) were retrieved from PubMed database, Cochrane Library, Embase database, China Notional Knowledge Infrastructure (CNKI), Wanfang database and VIP database and references listed in all studies. The data of RCT that met the inclusion criteria were extracted, and the quality was evaluated and cross-checked independently according to Cochrane Handbook for Systematic Reviews of Interventions, and then Meta-analysis was conducted by using StataMP 14.0 software.Results:A total of 16 studies and 1 090 patients were included. Compared with the control group, the experimental group had a higher complete remission rate and total effective rate, and the differences were statistically significant ( RR=1.63, 95% CI 1.40-1.89, P < 0.01; RR=1.39, 95% CI 1.27-1.51, P < 0.01). In terms of adverse reactions, the incidence of fever in the experimental group was higher than that in the control group, and the difference was statistically significant ( RR=2.06, 95% CI 1.54-2.75, P < 0.01). Conclusion:Meta-analysis showed that decitabine combined with CAG regimen has a better clinical efficacy in the treatment of elderly patients with AML, but there are more severe adverse reactions.
